This article aims to explain the current landscape of cell therapy manufacturing, including its challenges and solutions.

DOR/ISL is currently at the pre-registration stage of development in the US and is expected to launch in this market in 2026, ...

ImmunityBio has surged over 200% YTD, yet I see little fundamental justification for its current $10B enterprise value. Click here to read why IBRX is a Sell.

INSTI, two-drug regimen to demonstrate non-inferiority and a similar safety profile at Week 48 to BIC/FTC/TAF in adults living with HIV-1 who had not previously received antiretroviral ...

Immunocore reports fourth quarter and full year 2025 financial results and provides a business update KIMMTRAK (tebentafusp-tebn) Q4 net sales ...

Many people’s brains deteriorate as they age, becoming riddled with malfunctioning proteins that result in cell death and the ...

A 91-year-old man with a history of bladder carcinoma and left total knee arthroplasty was evaluated because of left knee pain. A culture of synovial fluid showed no growth. A diagnosis was made.

A new editorial perspective was published in Volume 17 of Oncotarget on February 20, 2026, titled "CAR-T therapy: Trailblazing CAR(ing) in cancer treatment." ...

On Thursday, Feb. 19, Ali May, an assistant professor at the Icahn School of Medicine at Mount Sinai presented her research on the various ways tissue resident macrophages shape embryonic salivary ...

In an early-stage clinical trial, half the patients with advanced undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma responded to the TIL therapy.